Loading company…
Nephris develops therapies targeting the progression of kidney disease, including diabetic nephropathy.
Founded in 2021 by Paolo Fiorina and Francesca D’Addio, Nephris is a pre-clinical biotech company focused on targets involved in kidney disease progression. It researches therapies for diabetic nephropathy intended to improve kidney function and prevent, treat, or reverse diabetic kidney disease. The company is based in Milan, Italy. In April 2022, it raised EUR 3 million in seed funding from Sofinnova Partners.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in